EMICIZUMAB DATA
Additional Topics
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Bone and Joint Health
Effect of Emicizumab Prophylaxis on Bone and Joint Health Markers in People with Haemophilia A Without Factor VIII Inhibitors in the HAVEN 3 Study
Kiialainen A, Niggli M, Kempton C, et al. Haemophilia. 2022. doi: 10.1111/hae.14642.
Bone and Joint Health Markers in Persons With Hemophilia A (PwHA) Treated With Emicizumab in the HAVEN 3 Clinical Trial
Kiialainen A, Castaman G, Chang T, et al. Presented at the Virtual NHF Scientific Meeting; August 1-8, 2020.
Hemophilia A and Mortality
Mortality in Congenital Hemophilia A - A Systematic Literature Review
Hay CRM, Nissen F, and Pipe SW. J Thromb Haemost. 2021; Suppl 1(Suppl 1):6–20.
Establishment of a Framework for Assessing Mortality in Persons With Congenital Hemophilia A and Its Application to an Adverse Event Reporting Database
Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. J Thromb Haemost. 2021; Suppl 1(Suppl 1):21–31.
Application of a Hemophilia Mortality Framework to the Emicizumab Global Safety Database
Peyvandi F, Mahlangu JN, Pipe SW, et al. J Thromb Haemost. 2021; Suppl 1(Suppl 1):32–41.
A Systematic Review of Mortality Statistics and Causes of Death in People With Congenital Hemophilia A (PwcHA)
Hay C, Nissen F, and Pipe S. Presented at the Virtual NHF Scientific Meeting; August 1-8, 2020.
A Contemporary Framework For Understanding Mortality in People With Congenital Hemophilia A (PwcHA)
Pipe S, Kruse-Jarres R, Mahlangu J, et al. Presented at the Virtual NHF Scientific Meeting; August 1-8, 2020.
An Analysis of Fatalities in Persons With Congenital Hemophilia A Reported in the FDA Adverse Event Reporting System (FAERS) Database
De Ford C, Kuebler P, Shang A, et al. Presented at the Virtual NHF Scientific Meeting: August 1-8, 2020.
Impact of Inhibitors on Hemophilia A Mortality in the United States
Walsh CE, Soucie JM, Miller CH, et al. Am J Hematol. 2015;90:400–405.
Real-World Experience
Emicizumab in Children: Bleeding Episodes and Outcome Before and After Transition to Emicizumab
Glonnegger H, Andresen F, Kapp F, et al. BMC Pediatr 2022;22:487.
Real-World Experience of Emicizumab Prophylaxis in Young Children With Hemophilia A: Retrospective Data From China
Liu G, Huang K, Li G, et al. Front Pediatr 2022;10:992267.
Real-World Data on Emicizumab Prophylaxis in the Milan Cohort
Arcudi S, Gualtierotti R, Marino S, et al. Haemophilia 2022;28:e141-e144.
Switching to Emicizumab: A Prospective Surveillance Study in Haemophilia A Subjects With Inhibitors
Dubé E, Merlen C, Bonnefoy A, et al. Haemophilia 2022. doi: 10.1111/hae.14685.
Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
Nissen F, Jiang Y, Hiew HJ, et al. Presented at ASH; December 10-13, 2022.
Emicizumab and Females With Hemophilia A: Case Series from ATHN 7
Recht M, Daoud N, Lee L, et al. Presented at ASH; December 10-13, 2022.
Safety and Efficacy of Emicizumab in People With Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)
Buckner TW, Carpenter SL, Kempton CL, et al. ISTH 2022; Oral presentation 40.4.
Real-World Experience on the Tolerability and Safety of Emicizumab Prophylaxis in Paediatric Patients With Severe Haemophilia A With and Without FVIII Inhibitors
Hassan E, Jonathan L, Jayashree M. Haemophilia 2021;27:e698-e703.
Emicizumab Initiation and Bleeding Outcomes in People With Hemophilia A With and Without Inhibitors: A Single-Center Report
Warren BB, Chan A, Manco-Johnson M, et al. Res Pract Thromb Haemost 2021;5:e12571.
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated With Emicizumab
Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. J Clin Med 2021;10(19):4303.
Emicizumab in Pediatric Hemophilia: Bleeding and Surgical Outcomes from a Single-Center Retrospective Study
Cohen CT, Diaz R. Pediatr Blood Cancer 2021;68:e29325.
Real-World Case Series and Summary of Current Literature of Infants and Toddlers With Severe Hemophilia A With Inhibitor on Prophylaxis With Emicizumab
Garcia J and Zia A. Pediatr Blood Cancer. 2021;68(5):e28942.
Emicizumab Prophylaxis in Haemophilia Patients Older than 50 Years With Cardiovascular Risk Factors: Real-World Data
Misgav M, Brutman-Barazani T, Budnik I, et al. Haemophilia. 2021;27(2):253-260.
Emicizumab Treatment and Monitoring in a Paediatric Cohort: Real-World Data
Barg AA, Livnat T, Budnik I, et al. Br J Haematol. 2020;191(2):282-290.
Real-World Use of Emicizumab in Patients With Haemophilia A: Bleeding Outcomes and Surgical Procedures
McCary I, Guelcher C, Kuhn J, et al. Haemophilia. 2020;26:631–636.
Emicizumab Prophylaxis in Patients With Haemophilia A With and Without Inhibitors
Ebbert PT, Xavier F, Seaman D, et al. Haemophilia. 2020;26:41–46.
Emicizumab Prophylaxis Among Infants and Toddlers With Severe Hemophilia A and Inhibitors-A Single-Center Cohort
Barg AA, Avishai E, Budnik I, et al. Pediatr Blood Cancer. 2019;66:e27886.